Cassia auriculata: Aspects of Safety Pharmacology and Drug Interaction

Table 1

Cardiovascular risk markers demonstrating cardiovascular safety of CA dosed animals.

	Control (0.5% NaCMC)	C. auriculata (mg kg^-1)
		HA		SFE
		500	1000	250	500	1000
Male
Homocysteine (𝜇mol L^-1)	10.2 ± 1.52	9.5 ± 2.15	5.8 ± 1.51**	7.7 ± 1.66	7.8 ± 3.10	5.5 ± 3.09**
CKMB (IU L^-1)	141.6 ± 26.65	143.8 ± 33.21	120.5 ± 20.0	135.7 ± 13.33	125.6 ± 31.55	120.4 ± 13.66
Troponin I (ng mL^-1)	0.64 ± 0.03	0.67 ± 0.05	0.56 ± 0.10	0.48 ± 0.09	0.61 ± 0.08	0.55 ± 0.06
Female
Homocysteine (𝜇mol L^-1)	11.0 ± 2.52	10.0 ± 1.52	6.6 ± 1.74*	6.9 ± 1.35	9.2 ± 1.85	6.5 ± 2.14*
CKMB (IU L^-1)	150.2 ± 30.27	138.9 ± 24.22	133.8 ± 15.88	145.5 ± 33.20	132.2 ± 30.9	135.5 ± 16.3
Troponin I (ng mL^-1)	0.51 ± 0.10	0.47 ± 0.07	0.56 ± 0.09	0.55 ± 0.04	0.55 ± 0.03	0.67 ± 0.04

Data are expressed as mean ± SD, 𝑛=6. ^∗𝑃<0.05, ^∗∗𝑃<0.01 significant decrease in homocysteine seen by 1000 mg kg^-1 dose of CA-HA and CA-SFE.